A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Summary

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  JNJ-90301900

  JNJ-90301900 will be injected intratumorally and/or intranodally.

• Biological
  Durvalumab

  Durvalumab will be administered as intravenous (IV) infusion as cIT.

• Radiation
  Concurrent Chemo/Radiation Therapy (cCRT)

  Radiation by intensity modulated radiation therapy (IMRT) will be administered.

• Drug
  Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin

  Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

• Drug
  Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

  Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Locations (40)